Intraoperative Ketamine Versus Lidocaine Infusion on Postoperative Cognitive Dysfunction in Patients Undergoing Hip Surgery

September 18, 2026 updated by: Marian Reda Abdou Gerges, Tanta University

Effect of Intraoperative Ketamine Versus Lidocaine Infusion on Postoperative Cognitive Dysfunction in Elderly Patients Undergoing Hip Surgery

This study aims to compare effects of ketamine versus lidocaine on postoperative cognitive dysfunction in geriatric patient undergoing hip surgery.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Hip arthroplasty remains one of the most commonly used and successful contemporary surgical interventions performed in older adults. Hip fractures in the elderly have emerged as a serious injury that incurs high medical costs and public resources due to long-term bed rest, limitations of independent daily living, or death, more than 28,000 hip fractures occur annually; this number is rapidly rising with the aging population) .

Despite successful surgery, patients still may suffer short- or long-term postoperative cognitive dysfunction , due to long operative times, extensive trauma, and the possibility of fat emboli .

POCD, which reflects a negative change in an individual's cognitive trajectory, has increasingly been recognized as a complication in elderly patients. It is characterized by disturbances in consciousness, orientation, thinking, memory, and executive function after surgical anesthesia .

The potential pathogenesis of postoperative cognitive dysfunction involves neuroinflammation and oxidative stress secondary to anesthesia and surgery. Post-surgery inflammation is characterized by increased levels of inflammatory cytokines and mediators and vascular permeability. Excessive inflammation can disrupt the body's immune system, potentially leading to certain inflammation-related conditions .

postoperative cognitive dysfunction is a neurological dysfunction which may last for weeks, months or years and can delay recovery, extend hospital stays, and even increase patient mortality. The incidence of postoperative cognitive dysfunction varies between 20 and 40% in patients over 60 years old. Therefore, it is important to develop new strategies to prevent postoperative cognitive dysfunction , especially in elderly patients . However, there is still unclear. on the methods and treatments used to prevent and treat postoperative cognitive dysfunction , including dexmedetomidine, ketamine, ulinastatin, parecoxib, midazolam, lidocaine, and dexamethasone.

Systemic lidocaine possesses analgesic, antihyperalgesic, prokinetic, and anti-inflammatory properties. It inhibits the release of proinflammatory cytokines and superoxide anions from activated neutrophils and blocks their accumulation at the injury site. The use of intravenous lidocaine infusions is associated with better pain relief, decreased risk of postoperative ileus, and improved enhanced recovery after surgery outcomes .

Ketamine, a non-competitive antagonist of N-methyl-d-aspartate receptors, exerts its primary mechanism of action by blocking N-methyl-d-aspartate receptors on gamma-aminobutyric acid interneurons and activating alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors. Ketamine possesses anti-inflammatory properties, including the reduction of microglia activation as well as downregulation of pro-inflammatory cytokines . Hence, this study aims to compare effects of ketamine and lidocaine on postoperative cognitive dysfunction in geriatric hip surgery patients.

This study aims to compare effects of ketamine versus lidocaine on postoperative cognitive dysfunction in geriatric patient undergoing hip surgery.

Study Type

Interventional

Enrollment (Actual)

120

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Tanta, Egypt
        • Tanta University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

66 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Both sexes of Elderly patient Aged >65 years.
  • American Society of Anesthesiologists classification I-III.
  • Undergoing hip surgery under spinal anesthesia.

Exclusion Criteria:

  • Patient refusal.
  • History of mental illness or scoring less than 8 using abbreviated mental test before operation as in table 3 .
  • Obvious sinus bradycardia (heart rate of <50 beats per minute) or other serious cardiovascular diseases.
  • Symptomatic cerebrovascular disease (such as previous stroke).
  • History of liver and kidney dysfunction.
  • Allergy to lidocaine or ketamine.
  • Metabolic disorders and fluid, electrolytes disturbances.
  • Alcohol dependence or drug abuse.
  • Redo surgery or infectious complications.
  • Central nervous system medications (antipsychotics, anticonvulsants, antiparkinsonian, antidepressants).
  • History of deep vein thrombosis.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group Ketamine

Patients will receive ketamine as a bolus (0.5 mg/kg) after induction of spinal anesthesia, followed by a continuous infusion (0.2 mg/kg. h) until the end of surgery.

Patients will receive ketamine as a bolus (0.5 mg/kg) after induction of spinal anesthesia, followed by a continuous infusion (0.2 mg/kg. h) until the end of surgery.

Experimental: Group Lidocaine

Patients will receive lidocaine as a bolus (1.5 mg/kg) after induction of spinal anesthesia, followed by a continuous infusion (2 mg/kg. h) until the end of surgery.

Patients will receive lidocaine as a bolus (1.5 mg/kg) after induction of spinal anesthesia, followed by a continuous infusion (2 mg/kg. h) until the end of surgery

Placebo Comparator: Group Placebo

Patients will receive placebo (saline) and administered in equal volumes and in the same manner as a control group.

Patients will receive placebo (saline) and administered in equal volumes and in the same manner as a control group.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Incidence of postoperative cognitive dysfunction
Time Frame: 3 days
3 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Postoperative pain score
Time Frame: 24 hours postoperatively

postoperative pain assessment with the Numerical rating Scale. Numerical rating Scale(0 represents "no pain") (1-3) mild pain; (4-6) moderate pain; (7-10) severe pain

24 hours postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 30, 2025

Primary Completion (Actual)

March 30, 2026

Study Completion (Actual)

March 30, 2026

Study Registration Dates

First Submitted

September 18, 2026

First Submitted That Met QC Criteria

September 18, 2026

First Posted (Actual)

September 24, 2026

Study Record Updates

Last Update Posted (Actual)

September 24, 2026

Last Update Submitted That Met QC Criteria

September 18, 2026

Last Verified

March 1, 2025

More Information

Terms related to this study

Other Study ID Numbers

  • 36265MD386/3/25

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

It will be available if it needed

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.